Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of $0.46, $0.04 better than the analyst estimate of $0.42. Revenue for the quarter came in at $216.6 million versus the consensus estimate of $217.46 million.

GUIDANCE:

Myriad Genetics sees Q4 2019 EPS of $0.48, versus the consensus of $0.48. Myriad Genetics sees Q4 2019 revenue of $220 million, versus the consensus of $225.3 million.

Myriad Genetics sees FY2019 EPS of $1.74, versus the consensus of $1.71. Myriad Genetics sees FY2019 revenue of $856 million, versus the consensus of $861.41 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.